evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

191 questions · 225 findings · 21 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 50 · 22.2%GRADE not reported 8 · 3.6%Very low 62 · 27.6%Low 55 · 24.4%Moderate 38 · 16.9%High 12 · 5.3%

Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo

Placebo (4 RCT; 789 participants)
4 findings from 1 review
Show 1 more finding

TMP/SMX vs placebo, no treatment or non‐PCP drug

All‐cause mortality ‐ sensitivity analysis · patients with Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients

TMP/SMX showed no clear difference in all cause mortality ‐ TMP/SMX versus placebo or no treatment compared with placebo, no treatment or non‐PCP drug (low certainty).

1 finding from 1 review

TMP/SMX vs placebo, no treatment or non‐PCP drug

Adverse events: severe adverse events requiring treatment discontinuation ‐ TMP/SMX versus placebo or no treatment Clinical and laboratory criteria and treatment discontinuations · patients with Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients

TMP/SMX showed no clear difference in adverse events: severe adverse events requiring treatment… compared with placebo, no treatment or non‐PCP drug (moderate certainty).

1 finding from 1 review

Lifestyle interventions vs placebo or usual care

Overall survival (24 months) · weight reduction in obesity to improve survival in women with endometrial cancer

It is very uncertain whether summary of findings table ‐ Lifestyle intervention changes overall survival (24 months) compared with usual care compared to placebo (very low certainty).

1 finding from 1 review

Lifestyle interventions vs placebo or usual care

Adverse events – musculoskeletal · weight reduction in obesity to improve survival in women with endometrial cancer

It is very uncertain whether summary of findings table ‐ Lifestyle intervention changes adverse events – musculoskeletal compared with usual care compared to placebo (very low certainty).

1 finding from 1 review

Lifestyle interventions vs placebo or usual care

Cardiovascular and metabolic event frequency (12 months) (Number of strokes, myocardial infarctions and hospitalisations for heart failure) · weight reduction in obesity to improve survival in women with endometrial cancer

Summary of findings table ‐ Lifestyle intervention showed no clear difference in cardiovascular and metabolic event frequency (6 months) compared with usual care compared to placebo (low certainty).

1 finding from 1 review

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy)

Adverse events (grade ≥ 3) · newly‐diagnosed EOC

It is very uncertain whether summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy changes any severe adverse event (grade 3 or higher) (G3+ SevAE ) compared with placebo (maintenance therapy) (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo (maintenance therapy)

Overall survival (OS) · platinum‐sensitive recurrent EOC

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in overall survival (OS) compared with placebo after chemotherapy (maintenance therapy) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo (maintenance therapy)

Progression‐free survival · platinum‐sensitive recurrent EOC

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… leads to lower progression‐free survival (PFS) compared with placebo after chemotherapy (maintenance therapy) (high certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo (maintenance therapy)

Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… may leads to higher any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with placebo after chemotherapy (maintenance therapy) (low certainty).

1 finding from 1 review